Skip to main content
  • Book
  • © 2005

Antirheumatic Therapy: Actions and Outcomes

Birkhäuser
  • Comprehensive and well structured according to classes of agents

  • Includes an outlook on future molecular targets

  • International authorship

Part of the book series: Progress in Inflammation Research (PIR)

Buying options

eBook USD 149.00
Price excludes VAT (USA)
  • ISBN: 978-3-7643-7726-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book USD 199.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (17 chapters)

  1. Front Matter

    Pages i-xiii
  2. Targeting DMARD therapy

    • Maria E. Suarez-Almazor
    Pages 25-47
  3. Pharmacoeconomic properties of disease-modifying antirheumatic drugs

    • Andreas Maetzel, Daniel H. Solomon
    Pages 49-67
  4. Future molecular targets

    • Keystone Edward C., Haraoui Boulos
    Pages 69-80
  5. Hydroxychloroquine

    • Bothwell Beau, Daniel E. Furst
    Pages 81-92
  6. Sulfasalazine

    • Cees J. Haagsma
    Pages 93-132
  7. Parenteral gold

    • Rolf Rau
    Pages 133-161
  8. Azathioprine

    • David Kanel, Barry Bresnihan
    Pages 163-173
  9. Methotrexate

    • Kevin Pile
    Pages 175-197
  10. Leflunomide

    • Alberta Hoi, Geoffrey Littlejohn
    Pages 199-219
  11. Cyclosporin

    • Arno W. R. van Kuijk, Ben A. C. Dijkmans
    Pages 221-236
  12. Tetracyclines

    • Kristin Bird, James R. O’Dell
    Pages 237-245
  13. Systemic glucocorticoids in rheumatoid arthritis

    • John R. Kirwan, Mark G. Perry
    Pages 247-264
  14. TNF-α inhibitors

    • Zuhre Tutuncu, Arthur Kavanaugh
    Pages 265-278
  15. Anakinra in rheumatoid arthritis

    • Barry Bresnihan
    Pages 279-291
  16. Combination therapy

    • Ernest Choy, Harold E. Paulus
    Pages 293-318
  17. Back Matter

    Pages 337-346

About this book

Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short­ term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor­ der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi­ cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long­ term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav­ elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.

Keywords

  • Arthritis
  • autoimmune disease
  • cell
  • chemistry
  • diseases
  • economics
  • medicinal chemistry
  • pharmacology
  • quality of life
  • research
  • rheumatism
  • rheumatoid arthritis
  • therapy
  • toxicity
  • transplantation

Editors and Affiliations

  • Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital Sydney, Sydney, Australia

    Richard O. Day

  • Carl M.Pearson Professor of Rheumatology, Los Angeles, USA

    Daniel E. Fürst

  • 546 Dept. of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands

    Piet L. C. M. Riel

  • Department of Rheumatology, St Vicent’s University Hospital, Dublin 4, Ireland

    Barry Bresnihan

Bibliographic Information

  • Book Title: Antirheumatic Therapy: Actions and Outcomes

  • Editors: Richard O. Day, Daniel E. Fürst, Piet L. C. M. Riel, Barry Bresnihan

  • Series Title: Progress in Inflammation Research

  • DOI: https://doi.org/10.1007/978-3-7643-7726-7

  • Publisher: Birkhäuser Basel

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Birkhäuser Basel 2005

  • Hardcover ISBN: 978-3-7643-6595-0

  • eBook ISBN: 978-3-7643-7726-7

  • Series ISSN: 1422-7746

  • Series E-ISSN: 2296-4525

  • Edition Number: 1

  • Number of Pages: XIII, 343

  • Topics: Health Sciences

Buying options

eBook USD 149.00
Price excludes VAT (USA)
  • ISBN: 978-3-7643-7726-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book USD 199.99
Price excludes VAT (USA)